GlassScriptPhysician profile
Carol B Eickhorn
NPI 1184726424
$12,251.88
in general payments reported to CMS, 2019-2025
58 companies · $48.07 in 2025
The $48.07 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,520 · 2022: $3,317 · 2023: $2,546 · 2024: $2,821 · 2025: $48.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,414.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,070.77 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $870.81 | 2021-2025 | |
| Amgen INC. | $644.37 | 2021-2024 | Uplizna, Aimovig |
| Alexion Pharmaceuticals, INC. | $584.65 | 2021-2024 | Ultomiris, Soliris |
| Ucb, INC. | $557.08 | 2021-2024 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $514.41 | 2021-2024 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $489.56 | 2021-2024 | Rytary |
| Janssen Pharmaceuticals, INC | $479.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $446.36 | 2021 | |
| Lilly USA, LLC | $369.20 | 2022-2024 | Amyvid, Emgality |
| Eisai INC. | $348.23 | 2021-2024 | |
| Genzyme Corporation | $322.01 | 2021-2024 | |
| Emd Serono, INC. | $316.16 | 2022-2024 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $299.85 | 2021-2024 | Hyqvia, Gammagard |
| Mallinckrodt Hospital Products INC. | $285.50 | 2021-2024 | Acthar |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $269.97 | 2021-2024 | Vyepti, Rexulti |
| Neurelis, INC. | $263.02 | 2021-2024 | Valtoco |
| Argenx US, INC. | $238.16 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $229.95 | 2022 | |
| Celgene Corporation | $228.84 | 2021-2023 | Zeposia |
| Mdd US Operations, LLC | $217.31 | 2022-2024 | Apokyn, Apokyn |
| Octapharma USA, INC. | $210.90 | 2021-2024 | Panzyga |
| Biogen, INC. | $205.55 | 2021-2024 | Plegridy, Vumerity, Tysabri |
| E.R. Squibb & Sons, L.L.C. | $186.77 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $179.59 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $174.98 | 2021-2024 | Ingrezza, Ongentys |
| Ani Pharmaceuticals, INC. | $167.20 | 2023-2024 | Purified Cortrophin Gel |
| Csl Behring | $159.18 | 2021-2024 | Hizentra |
| Tanabe Pharma America, INC. | $153.36 | 2021-2024 | |
| Genentech USA, INC. | $145.87 | 2022-2024 | Ocrevus |
| Jazz Pharmaceuticals INC. | $133.80 | 2022-2024 | |
| Impel Pharmaceuticals INC. | $120.49 | 2022-2023 | Trudhesa |
| Acadia Pharmaceuticals INC | $118.14 | 2021-2025 | Nuplazid, Daybue |
| Merz Pharmaceuticals, LLC | $117.37 | 2023-2024 | Xeomin |
| Grifols USA, LLC | $101.82 | 2021-2022 | |
| Pfizer INC. | $89.22 | 2021-2024 | |
| Harmony Biosciences LLC | $85.77 | 2023 | Wakix |
| Sk Life Science, INC. | $84.25 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $82.62 | 2021-2024 | Onpattro |
| Allergan, INC. | $79.22 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $77.62 | 2021-2023 | |
| Acorda Therapeutics, INC | $68.08 | 2021-2024 | Inbrija |
| Otsuka America Pharmaceutical, INC. | $57.77 | 2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $56.51 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $49.36 | 2023 | Aptiom |
| Aprecia Pharmaceuticals, LLC | $48.58 | 2023 | Spritam |
| Alfasigma USA, INC. | $48.32 | 2021 | |
| Boston Scientific Corporation | $35.66 | 2023-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $32.29 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.67 | 2021 | |
| Medtronic, INC. | $20.52 | 2023 | Reveal Linq |
| Tg Therapeutics, INC. | $20.15 | 2024 | |
| Supernus Pharmaceuticals, INC. | $18.04 | 2022 | |
| Avion Pharmaceuticals | $16.72 | 2022 | |
| Kyowa Kirin, INC. | $15.53 | 2023 | Nourianz |
| Astrazeneca Pharmaceuticals LP | $12.55 | 2022 | |
| Dynasplint Systems INC. | $6.78 | 2023 | Dynasplint |
| Corium, LLC | $3.48 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Eickhorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.